MedTrace Logo

Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis

NCT07716332 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-07-21

No results posted yet for this study

Summary

The purpose of this study is to compare the use of oral apixaban to subcutaneous enoxaparin for venous thromboembolism (VTE) prophylaxis in postpartum women at high risk for VTE. The primary goal is to evaluate medication adherence rates and patient satisfaction with the treatment.

Conditions

  • Postpartum
  • DVT Prophylaxis

Interventions

DRUG

Apixaban

Apixaban. 2.5 mg administered orally twice a day

DRUG

Enoxaparin

Enoxaparin 40 mg (or 60 mg for weight \> 91 kg) administered subcutaneously once a day

Sponsors & Collaborators

  • Ron Beloosesky MD

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-04-01
Completion
2027-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07716332 on ClinicalTrials.gov